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Abstract
Most common diseases demonstrate familial aggregation; the ratio of the risk for relatives of affected people to
the risk for relatives of unaffected people (the familial risk ratio)) > 1. This implies there are underlying genetic and/
or environmental risk factors shared by relatives. The risk gradient across this underlying ‘familial risk profile’, which
can be predicted from family history and measured familial risk factors, is typically strong. Under a multiplicative
model, the ratio of the risk for people in the upper 25% of familial risk to the risk for those in the lower 25% (the
inter-quartile risk gradient) is an order of magnitude greater than the familial risk ratio. If familial risk ratio = 2 for
first-degree relatives, in terms of familial risk profile: (a) people in the upper quartile will be at more than 20 times
the risk of those in the lower quartile; and (b) about 90% of disease will occur in people above the median.
Historically, therefore, epidemiology has compared cases with controls dissimilar for underlying familial risk profile.
Were gene-environment and gene-gene interactions to exist, environmental and genetic effects could be stronger
for people with increased familial risk profile. Studies in which controls are better matched to cases for familial risk
profile might be more informative, especially if both cases and controls are over-sampled for increased familial risk.
Prospective family study cohort (ProF-SC) designs involving people across a range of familial risk profile provide
such a resource for epidemiological, genetic, behavioural, psycho-social and health utilisation research. The
prospective aspect gives credibility to risk estimates. The familial aspect allows family-based designs, matching for
unmeasured factors, adjusting for underlying familial risk profile, and enhanced cohort maintenance.
Introduction
Traditionally, epidemiological designs in which subjects
in the same case-control group are independent of one
another have been used to study risks associated with
environmental exposures. With the advent of large-scale
genotyping, these approaches are now being used to
study risks associated with measured genetic factors,
usually common variants.
In this paper it is proposed that disease-specific family
cohort designs, in which subjects are enriched for familial
and genetic risk, have a number of advantages especially
for studying gene-environment and gene-gene interactions.
Although the examples below are largely based on cancer
studies, the issues raised are pertinent to other diseases.
What is familial aggregation?
Familial aggregation describes the increased risk of dis-
ease experienced by a defined group of relatives of
affected people. It is a feature of most common diseases,
including cancers. A measure of its strength is the
familial risk ratio, the ratio of the risk for relatives of
affected people to the risk for relatives of unaffected
people. For many common cancers, the typical approxi-
mately 2-fold familial risk ratio for first-degree relatives
might be considered modest but its implications do not
appear to have been widely appreciated. The following
discussion is about explanations of variation in risk
within a closed population, in the sense that people are
marrying within the population. It does not necessarily
apply to explanations of the wide variations in cancer
risks across populations.
Why is familial aggregation important?
For familial aggregation of a disease to be manifest there
must be at least some genetic and/or non-genetic causes
that are correlated between relatives. A person’s familial
risk is based on their status in regard to the familial
causes and the strengths of those causes with respect
t od i s e a s er i s k .S u p p o s et h e r ea r en familial causes,
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any medium, provided the original work is properly cited.C1,C 2, ..., Cn, for which a given person has values c1,c 2,
..., cn. Associated with these are relative risks of disease,
rc1,r c2, ..., rcn. Under the assumption that these risks act
independently, the familial risk profile of that person is
then determined by the population age- and sex-specific
incidence and the product of these relative risks, rc1.rc2...
rcn. This representation could be expanded to allow for
interactions.
As discussed below, it has been demonstrated theore-
tically using several mathematical models that the risk
gradient across the familial risk profile must be at least
an order of magnitude greater than the familial risk
ratio. The general conclusions of the different
approaches are essentially the same, and do not depend
on why the causes are correlated in relatives.
Familial risk models
Under a ‘major’ gene model (in the sense that there are
rare genetic variants that have a strong effect on disease
risk), Peto [1] showed that if these disease-predisposing
variants are strongly associated with risk, their rarity
means that they cannot explain more than a small pro-
portion of familial aggregation (in the population sense
above).
Independently of one another, Aalen [2] and Hopper
& Carlin [3] considered a continuously distributed
familial risk profile while Khoury and colleagues [4]
considered one or more familial causes that are binary
(i.e. present or absent). Their general conclusions are
similar.
Suppose the familial risk profile is on a scale for which
it is normally distributed and that disease risk increases
as a logistic function of the familial risk profile [3]; see
Table 1 and Figure 1.
Let RR = ratio of risk, RU, for people in the upper
quartile of the distribution of familial risk profile to the
risk, RL, for people in the lower quartile. This is a mea-
sure of the strength of familial causes across the popula-
tion. Let OR = ratio of the disease odds for first-degree
relatives of an affected person to the disease odds for
first-degree relatives of an unaffected person. This is the
familial risk ratio for first degree relatives and is a mea-
sure of the strength of familial aggregation of the dis-
ease. Let r = be the correlation between the familial risk
profiles of first-degree relatives. This is a measure of the
extent to which the familial causes are shared by
relatives.
Under this model, for fixed RR and r,O Ri sa l m o s t
independent of disease frequency across the range
0.001-0.1. For fixed RR, log OR is approximately linearly
related to r [3]. Table 1 shows OR for different values of
RR and r. An OR of about 2 occurs if r = 1 and RR = 9,
r = 0.6 and RR = 20, or r =0 . 3a n dR R=1 0 0 .E v e ni fr
= 1 (i.e. familial risk profiles are identical as they would
be for monozygotic twin pairs if all causes were genetic)
and there was a 100-fold inter-quartile risk gradient, the
familial disease risk would be 10, an order of magnitude
less.
Under a polygenic model, the normally distributed
familial risk profile is the result of multiple variants in
one or more, if not many genes. If their effects are inde-
pendent and additive, in the sense described by Fisher
[5], then the correlation between first-degree relatives is
r = 0.5. Table 1 shows that the inter-quartile risk ratio,
RR, must be at least 20 in order to explain a 2-fold
Table 1 Odds Ratio (OR) for risk of disease in first-degree
relatives of an affected person to risks of disease in first-
degree relatives of an unaffected person, as a function of
the inter-quartile risk ratio (RR) for underlying normally
distributed familial causes that are normally distributed,
correlated r in first-degree relatives, and for which risk is
a logistic function; see text and Hopper & Carlin (1992)
RR r = correlation in first-degree relatives
0.2 0.4 0.6 0.8 1.0
1.5 1.01 1.01 1.02 1.02 1.03
2 1.02 1.03 1.05 1.06 1.08
3 1.04 1.08 1.12 1.16 1.21
5 1.08 1.17 1.27 1.38 1.49
10 1.17 1.37 1.61 1.88 2.20
20 1.30 1.67 2.15 2.76 3.53
100 1.66 2.71 4.29 6.70 10.4
Figure 1 Under the polygenic multiplicative model, the
increasing line shows the lifetime risk as a function of familial
risk ratio for a disease with average lifetime risk 10%, r = 0.5
and OR = 2. The distribution of familial risk ratio for the population
is shown as a normal density curve with mean = median. Q1 and
Q3 are the lower and upper quartiles, respectively. RL and RU are
the lifetime risks for people in the lower and upper quartiles,
respectively. The dotted line indicates average (mean) lifetime risk.
RU/RL is at least 20; see Table 1 and Hopper & Carlin (1992).
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more than 5-times population risk, and people in the
lower quartile are at less than 25% of population risk.
Pharoah and colleagues [6] developed a polygenic
model (in which they refer to the familial risk profile as
the genetic risk profile) that assumes the effects of var-
iants are multiplicative and hence their genetic risk has
a log normal distribution. They estimated parameters
from UK breast cancer family data and showed that:
about 90% of cases were above the median of the popu-
lation genetic risk profile; see Figure 2 of [6], and half of
the cases occurred in the one-eighth of the population
whose risk is at least four times the median.
The percentages above depend on the model. The
familial risk profile is likely to be due to a mixture of
familial causes, but in theory it could always be trans-
formed to have a normal distribution, and the risk func-
tion must increase monotonically. While the true risk
function might differ from the shape shown in Figure 1,
the general conclusion that a very strong risk gradient
must exist between the extremes of familial risk profile
is unlikely to change.
Therefore, even for a disease for which there is only
what one might consider in epidemiological terms ‘mod-
est’ familial aggregation (such as a two-fold increased
risk for close relatives relatives of affecteds), people of
the same age and sex must differ greatly in their familial
risks of disease (e.g. a 20-fold or more difference in risk
between the quarter of the population at lowest familial
risk and the quarter of the population at greatest famil-
ial risk). This familial risk gradient is in addition to dif-
ferences due to ‘non-familial’ environmental or lifestyle
factors that are specific to individuals. Finding the
causes of even a modest proportion of familial aggrega-
tion of a disease could be a major step in understanding
the causes of the disease itself.
Figure 2 shows, for different groups of unaffected peo-
ple defined by their average familial risk relative to that
for the population, the distribution of their familial risk
profile for a disease with average (mean) lifetime risk of
5% and an OR = 2 for having an affected first-degree
relative, under the assumptions of the multiplicative
polygenic model. These parameter values have been
chosen to approximate the situation for colorectal can-
cer in a western country.
Figure 2(a) shows that the mode lifetime risk for peo-
ple from the population is about 2%, substantially less
than the average (5%). There is a long tail, but only a
very small proportion is at more than four times the
average risk (20%).
Figures 2(b), (c) and 2(d) show that, as average familial
risks of the groups of people increase, the distribution
moves to the right. Figure 2(b) shows, for people at on
average twice population risk (such as those with a first-
degree relative of colorectal cancer), that while the
mode is little changed the tail has spread. Figure 2(c)
shows, for people at on average four times population
risk (such as those with a two first-degree relatives with
colorectal cancer, or one first-degree with early onset
disease and a second-degree relative also affected), that
a substantial proportion are at more than four times
population risk. Figure 2(d) shows, for people at on
average eight times population risk (such as those fulfill-
ing the Amsterdam II criteria for Lynch syndrome), that
almost all are above population average risk and there is
Figure 2 Under the polygenic multiplicative model, for a
disease with average lifetime risk of 5%, the distribution of
lifetime risk for: (a) the population; and for people at increased
familial risk profile by on average (b) 2-fold; (c) 4-fold; and (c)
8-fold.
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the vast majority of the population.
Figure 2 could also apply to affected people. Under
the polygenic multiplicative model their familial risk
profile distribution is shifted to the right, so the distri-
bution of their lifetime risk (at birth) is not the same as
for the population. In the current example where OR =
2, it is that shown in Figure 2(b), while for affecteds
with an affected first-degree relative it is that shown in
Figure 2(c), and so on. Consequently, the familial risk
factor profiles of cases with a strong family history are
quite different from those of people in the population
(cf. Figure 2(d) with Figure 2(a)).
Is there empirical evidence for a wide variation in
familial cancer risks?
Evidence consistent with there being a wide variation in
familial risk profile for breast cancer risk comes from a
study of monozygous (MZ) twin pairs [7]. Within pairs,
the breast cancer incidence for the genetically-identical
twins of affected women was constant with time, at least
beyond age 30 years, and about twice the incidence of
cancer in the contralateral breasts of affected women
(which was also a constant with time). This was inter-
preted in terms of a simple model that proposed the
most extreme instance of variation, the existence of two
types of women: those at risk, and those not at risk, of
breast cancer. Studies of risk factors for women ‘at risk’
were then conducted by comparing the time to onset for
MZ pairs concordant for breast cancer, and asking twins
to compare one another for the timing of early life events
such as the onset of puberty [8]. They found that “within
the most genetically susceptible subgroup of twin pairs,
[there was a] strong influence of earlier puberty on the
age at the diagnosis of breast cancer and [an] absence of
linkage to hormonal milestones later in life”. The authors
concluded that “most cases of hereditary breast cancer
are not related to cumulative hormone exposure and ...
instead result from an unusual sensitivity to pubertal hor-
mones. Associations between breast cancer and early
menarche and those with reproductive milestones in
adulthood may reflect different genotypes”.
How much familial aggregation is explained by
known risk factors?
For most diseases, the known so-called “environmental”
or life-style risk factors identified by e.g. questionnaires,
do not have a strong enough association with risk (e.g.
RR at most 2 or 3), and/or do not have a strong enough
correlation between relatives (e.g. r < 0.4), to individu-
ally explain much familial disease risk; see Table 1. Even
for smoking and lung cancer, for which RR might be 10
and r = 0.2-0.4, the predicted OR for familial disease
risk would be less than 1.4.
For breast cancer, the rather weak familial correlations
of the established questionnaire-derived risk factors
would result in ORs of at most 1.1. Therefore, the famil-
ial components of these environmental factors, as mea-
sured by questionnaires, might explain about 10% of
familial aggregation for this disease [3]. These estab-
lished risk factors predict a 3.5-fold risk gradient
between extreme quintiles [6]. Referring to Table 1 with
e.g. RR = 3.0 and r < 0.5, it can be seen that this gradi-
ent is also consistent with an OR < 1.1.
Measurement error attenuates estimates of both the
risk gradient and the correlation between relatives. Con-
sequently, the questionnaire-measured risk factors are
perhaps poor surrogates for underlying factors which, if
they could be measured better, would be associated with
greater risks and be more strongly correlated in rela-
tives. It would be naïve to conclude that, because the
established environmental factors explain at most 10%
of familial aggregation of breast cancer, all of the
remaining 90% is due to genetic factors.
Genetic mutations associated with high personal
risks are typically so rare that they explain only a small
proportion of familial aggregation, as demonstrated
theoretically by Peto [1]. It has been shown empirically
that the rare mutations in BRCA1 and BRAC2 asso-
ciated with a 10-fold or more increased risk of breast
cancer [9] account for about a modest 1.2-fold
increased familial risk, around 20% of population
familial aggregation [10,11]. Similar considerations
apply to other hereditary cancer syndromes, such as
hereditary non-polyposis colorectal cancer for which
mutations in the DNA mismatch repair genes explain
a similar proportion of the increased risk to relatives
across the population [12].
The recently identified common variants associated
with cancers such as those of the breast, colorectum
and prostate (e.g. [13-16]) explain, in a statistical
sense, a few more percent of familial aggregation (see
b e l o w ) .I ti si m p o r t a n tt on o t et h a ta l m o s ta l lt h ev a r -
iants identified to date are not necessarily functional,
let alone ‘causal’, although some have claimed indirect
evidence of causality based on biological arguments (e.
g. [17]). The tight linkage disequilibrium that has
helped identify common variants associated with dis-
ease makes it problematic to tease out which, if any, is
causal using case-control designs due to collinearity (i.
e. high correlation between estimates of association
with variants that are highly correlated with one
another). The ‘common disease, common cause’
hypothesis is not necessarily supported by these obser-
v a t i o n s .M u c hr e m a i n st ob el e a r n ta b o u tw h ym o s t
common cancers (and other common diseases) are
familial, in a population sense, and the vast majority of
their familial causes are as yet unknown.
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underlying familial risk profile?
Traditionally, studies of putative environmental, lifestyle
and genetic risk factors have compared affecteds (cases)
with unaffecteds (controls). When sampling controls,
great attention has usually been paid to controlling for,
either by design or in the analysis, potential confounding
factors - but not necessarily for underlying familial risk
profile. Cases and controls are usually either matched,
individually or as groups, for age and often sex. If not,
statistical adjustment for any differences in the age and
sex distributions of cases and controls is a virtual neces-
sity. Some analyses adjust for family history, but this is
usually limited to self-reports (rarely verified) for first-
degree relatives only and so captures little information
on actual familial risk profile; see next section.
If a disease exhibits even modest familial aggregation,
mathematical models suggest that cases and controls
will be for underlying familial causes. More than half
the controls will be below population risk, and the vast
majority of cases above population risk. Adjusting for
whether or not there are any affected first-degree rela-
tives will explain only a small amount of these differ-
ences in underlying familial causes between cases and
controls. The strong risk gradient for familial causes
(Figure 1) is not dissimilar to that usually observed for
age as the horizontal axis, especially for cancers of
adult onset. Therefore, given that so much attention is
paid to age in the design and analysis of association
studies,
Note: the above discussion is relevant to ‘characteris-
taion’ studies which aim to estimate risk associations.
This is distinct from ‘discovery’ studies that aim to
find genetic risk factors, in which case more power is
obtained by over-sampling cases with characteristics
predictive of having a genetic aetiology (e.g. early-
onset, family history, etc.) and over-sampling controls
for characteristics predictive of not having a genetic
aetiology (e.g. old age, no family history, etc.); see next
section.
What predicts a person’s familial risk profile?
For most diseases, the strongest known indicators of a
person’s familial risk profile are: (i) their genotype for
known susceptibility genes, (ii) having the disease itself,
the more so the earlier the age at onset, and (iii) having
a family history of the disease, the more so the greater
the number of, the closer the relationship to, and the
earlier the age at onset of, affected relatives. It is also
emerging that, at least for some common cancers such
as those of the colorectum and breast, specific tumour
characteristics are good indicators of their particular
genetic causes, especially if the tumour developed at a
young age for the particular cancer [18,19].
For colorectal and some other tumours, evidence of
microsatellite instability, morphological characteristics
and, most importantly, absence of staining for specific
mismatch repair gene proteins strongly suggest that the
affected person, especially if onset is before age 45 years,
has a germline mutation in a mismatch repair gene that
confers a high risk of cancers of the colon, rectum, and
of other sites [12,18]. Specific morphological characteris-
tics of breast cancers are predictive of the presence of
mutations in BRCA1 and BRCA2 which predispose to
breast and ovarian cancers, particularly if they occur in
women before the age of 40 years [19].
Disease-predictive biomarkers that are correlated in
relatives provide another means for categorising people
according to their familial risk profile. For example, age-
and BMI-adjusted mammographic density for breast
cancer, number of polyps for colorectal cancer, skin col-
our and naevi (dysplastic moles) for melanoma, and
baldness for prostate cancer.
That is, there are multiple measurable indicators of a
person’s familial risk profile. Unfortunately, they tend to be
rather weak predictors except in the extreme. For example,
the probability of carrying a germline mutation in BRCA1
or BRCA2 is low unless a woman has a very strong family
history of breast and/or ovarian cancer [10,11].
How to adjust for familial risk profile?
Historically, statistical adjustment for familial risk profile
has been based on simple classifications of family history.
Far more powerful approaches can be achieved by taking
into account what is known about familial aspects of the
disease and building statistical models using family data.
This requires population-based studies and a high level
of biostatistical competence, and has been demonstrated
by development of the BOADICEA model for breast can-
cer [20]. While it is well known that use of this model
produces estimates of the probability a women carries a
BRCA1 or BRCA2 mutation, it also estimates of risks of
breast and ovarian cancers based on the genetic, personal
and family history data provided by the user. The pre-
dicted familial risk profile (Predicted FRP) can then be
used for analyses of e.g. modification of risk association
by predicted familial risk profile; see (iii) below. It could
also use information on other measured familial risk fac-
tors. Just as likelihood methods and the assumptions of
Mendelian inheritance allow, in effect, prediction of the
probability distribution of unmeasured genotypes based
on measured family genotypes and the fitted model, the
same could be undertaken for non-genetic familial risk
factors if the correlation structure between relatives was
known or well-estimated.
Therefore, based on personal and family history data
and any other information on familial or genetic risk,
subjects in a study can be ranked on their familial risk
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their estimated cumulative risks to a given age. These
can then be used as a covariate when wishing to assess
the influence of measured risk factors, such as lifestyle
factors or measured genetic variants; see below. This is
an area for future statistical research.
What about studies of gene-environment interactions?
To date, little epidemiological research has been con-
ducted focusing solely on people from the upper end of
the familial risk profile distribution. Should gene-environ-
ment interactions, and for that matter gene-gene interac-
tions, exist in the way posited by many (see e.g. [21]), the
associations with disease of environmental exposures, life-
style factors, and genetic modifiers might be much more
pronounced for people in the upper end of the population
distribution of familial risk profile (see Figure 2).
The associations might also differ, in magnitude and
even direction, from those when controls are unselected
for familial risk profile. For example, it has been found
that the small subgroup of women who have a germline
mutation in BRCA1 could be at a considerably reduced
risk of breast cancer if they use contemporary oral con-
traceptives for a year or more [22], whereas the conven-
tional wisdom is that for other women use of current
oral contraceptives is associated with a small and transi-
ent increase in risk [23]. If this observation is confirmed
by other studies, especially if using a prospective design,
it will lead to a deeper understanding of how oral con-
traceptives influence breast cancer risk (see Discussion;
[22]). It also has implications for female BRCA1 muta-
tion carriers, as it appears that oral contraceptive use is
associated with a reduction in risk of ovarian cancer, the
more deadly consequence of their genetic heritage [24].
Much remains to be learnt about the risks for people at
increased or even high familial, if not genetic, risk.
How can studies be designed to identify most effectively
and efficiently the environmental, or genetic, modifiers of
risk for those at increased risk due to familial, including
specific genetic, causes?
One approach would be to conduct a case-control study,
but over-sample controls for indicators of increased
familial risks. This is difficult if sampling is based on
unrelated controls, because the only indicator of familial
risk profile is family history and putative controls have
to be approached first to obtain this information. Self-
report information on family history can be of dubious
quality for all but a few common cancers [25].
Prospective family study cohort (Prof-SC;
pronounced “prophecy”) designs
A family-based cohort in which members are over-
sampled because they have a family history or other
indicators of being at increased if not high familial risk
(see above) has a number of advantages, in particular
for studying environmental and genetic factors relevant
to people at increased familial risk, and especially if pro-
spective. In this design, members of the cohort are fol-
lowed from a designated time point (e.g. recruitment at
baseline, or birth) and outcomes (incident cases) identi-
fied. By definition of the cohort, all of these incident
cases will be ‘familial’, in that they must have a family
history of the disease. This is in stark contrast to the
usual case-control and cohort studies in which the vast
majority of incident cases do not have a family history,
at least not in first- or second-degree relatives. Further-
more, depending on how the family cohort is ascer-
tained, some members might be affected at baseline.
This raises the prospect of studying the risks of a subse-
quent cancer in people with both a personal and family
history of the disease, another group enriched for famil-
ial if not genetic risk factors. Due regard, of course,
must be given to the potential for survivor bias of esti-
mates if people affected at baseline were diagnosed
some time prior to recruitment to the cohort. Some
examples of prospective breast and colorectal cancer
family study cohorts are described in the Appendix.
(i) Incident cases will be more similar to controls in
terms of their familial risk profile. In practice it will be
hard if not impossible to match perfectly for unmea-
sured familial risk, except perhaps using MZ twin pairs,
and cases will always be enriched for causes. For exam-
ple, even if carriers of a given disease-predisposing
genetic variant or mutation are studied, cases will on
average be enriched for modif i e r so fr i s k .( A sd i s c u s s e d
above, statistical adjustments can be made for familial
risk profile using family risk models.) .
(ii) People with a higher familial risk profile might be
more, or even less, susceptible to environmental and
lifestyle factors. Risk factors for people at increased if
not high constitutional risk might be more easily identi-
fied provided sufficiently large numbers can be studied,
and the prospective nature of the cohort will provide
credible information.
(iii) Studies would be enhanced by having indicators of
familial risk profile measured for at least one member
per family. If the cohort includes people across a wide
range of familial risk profile, incident case-control com-
parisons can also be stratified or analysed as a function
of Predicted FRP. For example, the disease association
with a given exposure could be estimated as a function
of Predicted FRP (provided information of the given
exposure was not used in calculation of the Predicted
FRP). Assessing if the associations with risk factors vary
with Predicted FRP provides a means for gathering evi-
dence on the possible existence of familial interactions,
such as gene-environment and gene-gene interactions.
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standard prospective cohort studies, e.g. using survival
analysis techniques such as Cox proportional hazard
regression models with age as the time axis. Calculation
of person-time would begin at baseline and end at the
earliest of date of diagnosis since baseline, date of death,
or date lost to follow-up. Censoring can also be based
on date of prophylactic surgery or uptake of screening
modalities, depending on the availability of data. The
fact that some families contribute multiple members to
the cohort, and thereby induce potential dependence,
can be easily handled by e.g. using robust estimates of
standard errors. Standard methods for predicting statis-
tical power can be applied, though the familial nature of
the cohort provides a complexity that in practice might
not be critical in this regard.
(v) Maintenance of the cohort is likely enhanced by its
familial nature. Excellent response can be achieved in
conducting such family-based cohorts especially if there
are multiple members per family who can help in tra-
cing persons who have moved or who would otherwise
be lost to follow-up; see below. For example, from a 10
year follow-up of Australian breast cancer families we
were able to locate and re-contact at least one member
for more than 90% of families, and obtained question-
naires and interviews for more than 80% of the family-
based cohort. Family members can also help update cri-
tical outcome data on relatives who cannot be traced or
are deceased.
(vi) Sub-studies can be conducted separately for peo-
ple affected at baseline so that risk of second cancers
can also be studied within this design. As mentioned
above, these people will be enriched for familial and
genetic risk factors.
(vii) In order to restrict the costs of studies that
involve expense in determination of exposure, such as
those that involve genome scanning, gene sequencing or
genotyping, molecular assays, etc., controls can be
selected within the cohort to match cases in much the
same way as this would be undertaken in a cohort of
unrelated people. By conducting this within a family
design, family-based controls can be included. This
would necessitate some complexities in the statistical
analysis, but these can be addressed (e.g. [26,27]) and
the results might provide new information on gene-
environment interactions.
(viii) The family nature of the cohort also allows for
within-family designs, such as sibling case-control stu-
dies. These are important due to the natural control
they provide for potential confounding by ethnicity, or
population stratification as it is referred to in the genetic
literature, and for other unmeasured familial risk factors.
(ix) Given the increasing difficulty in obtaining high
response from population sampling, family controls
might become even more important in the future. For
example, by also studying sister controls we have found
that population-based controls, but not sister controls,
might be unwittingly selected for breast cancer risk fac-
tors correlated with socio-economic status, educational
achievement, marital status and age at menarche, even if
a high response is achieved [28].
( x )B yf o l l o w i n gf a m i l i e sw i t hag i v e nd i s e a s eo v e r
time, additional cases of the disease will emerge in those
families segregating high-risk mutations (unless the
families know of their mutation status and are undertak-
ing measures to reduce the incidence of disease). This
will allow the conduct of prospective studies of both the
genetic and non-genetic modifiers of risk for mutation
carriers. The same applies to the modifiers of risk for
people with increased risk at baseline (e.g. due to having
at least one affected relative, or a high Predicted FRP).
(xi) This will also allow targeting of families for gene
discovery studies using classic linkage techniques, candi-
date genes approaches (including genome-wide associa-
tion studies), and with the advent of new sequencing
technologies, even whole genome or whole exome
sequencing [29].
(xii) The cohorts can also be used for behavioural,
psycho-social and health utilisation research, for exam-
ple by asking participants about their efforts and atti-
tudes to screening and risk reduction. Little is known
about how people at known or suspected high familial
risk are responding to the inherent challenges, and
those studies of actual behaviour have been for the most
part of highly-selected, self-identified groups typically
identified through clinics. The familial cohorts talked
about here would provide information about how people
in the general population are coping, and hopefully pro-
vide information to improve health outcomes for these
people at increased if not high familial risk.
Summary
Genetic discoveries will inevitably reshape public health
strategies because people of the same age and sex are
nowhere near ‘equal’ in terms of underlying risk.
Focussing on familial aspects of risk alone, people differ
remarkably even for diseases that show only modest
familial aggregation. The use of family-based research
designs is likely to make future epidemiological studies
much more informative as they will obtain higher levels
of participation and follow-up, and will utilise controls
better matched to cases for familial risk profile. People
at high familial risk might be more, or differently, sus-
ceptible to specific environmental and genetic risk fac-
tors than those at lower familial risk. Genetic
epidemiology might well benefit from studying people
across a range of familial risk, especially if over-sampled
for those at high risk, and using a prospective design.
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Registries (CFRs)
The Breast and Colon Cancer Family Registries (CFRs)
are resources of families, data, biospecimens, researchers
and community representatives established for colla-
borative research on breast and colorectal cancer. These
international registries were initiated in the 1990’sb y
the National Cancer Institute (NCI USA). Researchers
from the USA, Canada, Australia and New Zealand have
recruited volunteer families using common question-
naires and protocols. Data are collated at a centralized
Informatics Support Center.
The Vision of the CFRs is to realize the full potential of
collaborative research involving breast and colorectal
cancer families to reduce the global impact of these
diseases
The enrolled families span the continuum of risk, from
population-based series to families selected for a variety
of high risk features (early-onset disease, strong family
history). A variety of different types of controls (related,
unrelated) were also recruited in the same comprehen-
sive manner as the cases. The flexible designs, large
numbers of participants, and range of material and
information available provide a powerful resource to
address many important research questions.
The Breast CFR has collected lifestyle, medical his-
tory, and family history data from more than 40,000
women and men from 13,000 families with and without
breast cancer [30], including:
- 7,500 families containing at least one member with
breast cancer have been sampled using population com-
plete cancer registries
- 3,000 families have been randomly sampled from the
population
- 2,500 families with a strong family history of breast
cancer have been recruited through cancer family
clinics
Lymphocytes, plasma, blood cards, and DNA are avail-
able from 20,000 participants, including 10,000 women
who have had breast cancer. For most probands and
other prioritized samples, EBV-transformed lymphoblas-
toid cell lines are available (8,000). Biospecimens are
collected and processed according to a common stan-
dardized protocol. Families are being tested for muta-
tions in BRCA1, BRCA2 and the other major breast
cancer susceptibility genes. To date more than 1,600
carriers of deleterious mutations in BRCA1 and BRCA2
have been identified. Tumor samples have been col-
lected for 5,000 cases, and 3,500 of these have had a sys-
tematic pathology review. Recruitment of families began
in 1996 and all participants are being followed up 10
years after recruitment to update personal and family
histories, and expand recruitment if new cases have
occurred since baseline.
The Colon CFR has collected lifestyle, medical his-
tory, and family history data from more than 38,000
men and women from 13,200 families with and without
colorectal cancer [31], including:
- 8,000 families containing at least one member with
colorectal cancer have been sampled using population
complete cancer registries
- 4,000 families have been randomly sampled from the
population
- 1,200 families with a strong family history of color-
ectal cancer have been recruited through cancer family
clinics
DNA is available from 26,000 participants, of whom
9,200 have had colorectal cancer. Over 2,200 families
have been tested for mutations in DNA mismatch repair
genes. To date more than 1,000 carriers of deleterious
mutations have been identified. Tumour samples have
been collected for 8,000 cases, and more than 6,000 of
these samples have had molecular testing and pathology
review. Recruitment of families began in 1997 and all
participants are being followed up every 5 years to
update personal and family histories, and expand
recruitment if new cases have occurred since baseline.
The researchers who established the CFRs, as well as
external researchers, are equally able to conduct ethi-
cally-approved studies using the CFRs. Studies can
involve use of data and/or biospecimens and even
further involvement of participants, though this must be
done through the local recruitment investigators. To
apply to conduct collaborative research with the CFRs,
see http://epi.grants.cancer.gov/CFR/.
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